Inhibrx Biosciences, Inc.
INBX
$111.66
-$1.21-1.07%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -36.65M | -33.44M | -32.83M | -35.26M | -28.65M |
| Total Depreciation and Amortization | 523.00K | 537.00K | 564.00K | 583.00K | 661.00K |
| Total Amortization of Deferred Charges | 1.29M | 732.00K | 642.00K | 638.00K | 626.00K |
| Total Other Non-Cash Items | 3.62M | 3.14M | 3.22M | 3.63M | 3.21M |
| Change in Net Operating Assets | 1.30M | -8.99M | -1.72M | -3.42M | -5.80M |
| Cash from Operations | -29.92M | -38.03M | -30.12M | -33.82M | -29.95M |
| Capital Expenditure | -- | -- | 0.00 | -10.00K | 0.00 |
| Sale of Property, Plant, and Equipment | -- | -- | 0.00 | 3.00K | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | 0.00 | -7.00K | 0.00 |
| Total Debt Issued | 0.00 | 74.99M | 0.00 | 0.00 | 0.00 |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.60M | 471.00K | 1.25M | 352.00K | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 0.00 | 0.00 | 0.00 |
| Cash from Financing | 1.60M | 75.46M | 1.25M | 352.00K | 0.00 |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -28.31M | 37.44M | -28.87M | -33.48M | -29.95M |